Evidence map›Paper›PMID 35873301›Full record

ArticleOpen forum infectious diseases2022

COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health.

Stephanie A Richard, Nusrat J Epsi, David A Lindholm, Allison M W Malloy, Ryan C Maves, Catherine M Berjohn, Tahaniyat Lalani, Alfred G Smith, Rupal M Mody, Anuradha Ganesan and 20 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Health-related Quality of Life in European Older Adults with Respiratory Syncytial Virus Over Three Respiratory Syncytial Virus Seasons.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 10 institutions in 1 country.

Stephanie A RichardInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-0530-384X
Nusrat J EpsiInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
David A LindholmBrooke Army Medical Center, Fort Sam Houston, Texas, USA.
Allison M W MalloyUniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Ryan C MavesInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Catherine M BerjohnUniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Tahaniyat LalaniInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-9361-2991
Alfred G SmithNaval Medical Center Portsmouth, Portsmouth, Virginia, USA.
Rupal M ModyWilliam Beaumont Army Medical Center, El Paso, Texas, USA.
Anuradha GanesanInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Nikhil HuprikarUniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Rhonda E ColomboInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Christopher J ColomboUniformed Services University of the Health Sciences, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-5499-3368
Cristian MadarTripler Army Medical Center, Honolulu, Hawaii, USA.
Milissa U JonesUniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Derek T LarsonNaval Medical Center San Diego, San Diego, California, USA.
Evan C EwersFort Belvoir Community Hospital, Fort Belvoir, Virginia, USA.
Samantha BazanCarl R. Darnall Army Medical Center, Fort Hood, Texas, USA.
Anthony C FriesUS Air Force School of Aerospace Medicine, Dayton, Ohio, USA.
Carlos J MaldonadoWomack Army Medical Center, Fort Bragg, North Carolina, USA.
Mark P SimonsInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Julia S RozmanInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Liana AndronescuInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Katrin MendeInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
David R TribbleInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Brian K AganInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-5114-1669
Timothy H BurgessInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Simon D PollettInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
John H PowersClinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
EPICC COVID-19 Cohort Study Group
Henry M. Jackson Foundation · USFrederick National Laboratory for Cancer Research · USUniformed Services University of the Health Sciences · USNaval Medical Center San Diego · USCarl R. Darnall Army Medical Center · USMadigan Army Medical Center · USNaval Medical Center Portsmouth · USWomack Army Medical Center · USAlexander T. Augusta Military Medical Center · USBrooke Army Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patient-reported outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are an important measure of the full burden of coronavirus disease (COVID). Here, we examine how (1) infecting genotype and COVID-19 vaccination correlate with inFLUenza Patient-Reported Outcome (FLU-PRO) Plus score, including by symptom domains, and (2) FLU-PRO Plus scores predict return to usual activities and health. Methods: The Results: Among the 764 participants included in this analysis, 63% were 18-44 years old, 40% were female, and 51% were White. Being fully vaccinated was associated with lower total scores (β = -0.39; 95% CI, -0.57 to -0.21). The Delta variant was associated with higher total scores (β = 0.25; 95% CI, 0.05 to 0.45). Participants with higher FLU-PRO Plus scores were less likely to report returning to usual health and activities (health: hazard ratio [HR], 0.46; 95% CI, 0.37 to 0.57; activities: HR, 0.56; 95% CI, 0.47 to 0.67). Fully vaccinated participants were more likely to report returning to usual activities (HR, 1.24; 95% CI, 1.04 to 1.48). Conclusions: Full SARS-CoV-2 vaccination is associated with decreased severity of patient-reported symptoms across multiple domains, which in turn is likely to be associated with earlier return to usual activities. In addition, infection with the Delta variant was associated with higher FLU-PRO Plus scores than previous variants, even after controlling for vaccination status.

Indexed as

COVID-19patient-reported outcomesSARS-CoV-2symptomsvaccine breakthrough

Identifiers

PMID35873301
PMCPMC9214183
OpenAlexW4281617898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.